This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Accuray, TrueNorth Medical Physics Collaborate on Radiation Oncology Support MT
Accuray Incorporated and TrueNorth Medical Physics LLC Sign Agreement to Provide Radiation Oncology Support Intended to Advance Cancer Care for More Patients CI
Sector Update: Health Care Stocks Softer Wednesday Afternoon MT
Accuray Secures Approval for Precision Treatment Planning System MT
Accuray Incorporated Announces Approval of the Accuray Precision Treatment Planning System by China's National Medical Products Administration CI
Accuray Incorporated Announces Executive Changes, Effective May 17, 2024 CI
Earnings Flash (ARAY) ACCURAY INCORPORATED Posts Q3 Revenue $101.1M, vs. Street Est of $113.6M MT
Earnings Flash (ARAY) ACCURAY INCORPORATED Posts Q3 Revenue $101.1M, vs. Street Est of $113.6M MT
Transcript : Accuray Incorporated, Q3 2024 Earnings Call, May 01, 2024
Accuray Incorporated Provides Earnings Guidance for the Year 2024 CI
Accuray Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
Accuray Incorporated Showcases Advances in Radiation Therapy Solutions Designed to Improve the Cancer Treatment Experience at ESTRO 2024 CI
Accuray Incorporated Expands Global Training Center Network with Opening of New Facility in Genolier, Switzerland CI
Accuray Incorporated Announces New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can Be Effectively Treated in 5 Days Using the Accuray CyberKnife System CI
Roth MKM Starts Accuray With Buy Rating, $9 Price Target MT
Quebec Cancer Center Is First in Canada to Treat Cancer Patients Using the Accuray Radixact System CI
Transcript : Accuray Incorporated, Q2 2024 Earnings Call, Jan 31, 2024
Earnings Flash (ARAY) ACCURAY INCORPORATED Posts Q2 Revenue $107.2M, vs. Street Est of $106.7M MT
Accuray Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Accuray Incorporated Reaffirms Revenue Guidance for the Third Quarter and Full Fiscal Year 2024 CI
Accuray Incorporated Announces the Providence Swedish Radiosurgery Center in Seattle Invests in Second Accuray Cyberknife System CI
Accuray Insider Sold Shares Worth $161,624, According to a Recent SEC Filing MT
B. Riley Trims Accuray's Price Target to $6.50 From $7.50 on Lower Multiple, Maintains Buy Rating MT
Transcript : Accuray Incorporated, Q1 2024 Earnings Call, Nov 07, 2023
Accuray Incorporated Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Chart Accuray Incorporated
More charts
Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells, and supports solutions that are designed to deliver radiation treatments. Its solutions are designed to advance patient care during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, the Company also provides services, which include post-contract customer support (warranty period services and post warranty services), installation services, training, and other professional services.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.65 USD
Average target price
6 USD
Spread / Average Target
+263.64%
Consensus
  1. Stock Market
  2. Equities
  3. ARAY Stock
  4. News Accuray Incorporated
  5. Earnings Flash (ARAY) ACCURAY INCORPORATED Posts Q2 Revenue $107.2M, vs. Street Est of $106.7M